Solid forms of Pitolisant or its salt are provided. Also provided are solid dispersions of Pitolisant or salt thereof in amorphous form and at least one suitable pharmaceutically acceptable excipient. The process for preparing solid dispersion of Pitolisant or salt thereof is also provided.
Solid forms of Pitolisant or its salt are provided. Also provided are solid dispersions of Pitolisant or salt thereof in amorphous form and at least one suitable pharmaceutically acceptable excipient. The process for preparing solid dispersion of Pitolisant or salt thereof is also provided.
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
2.
A PROCESS FOR THE PREPARATION OF SOLID FORMS OF N-[4(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-3-YL) PYRIDINE-3-CARBOXAMIDE HYDROGEN CHLORIDE
The present invention relates to a process for the preparation of solid-state forms of N-[4(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H- pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride. More specifically, the present invention relates to a process for the preparation of solid dispersion of N-[4(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyra zol-3-yl) pyridine-3-carboxamide hydrogen chloride with at least one pharmaceutically acceptable excipient without isolating N-[4 (Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyra zol-3-yl) pyridine-3-carboxamide hydrogen chloride. Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
The present invention relates to solid forms of N-(8-[2-Hydroxybenzoyl]-Amino) caprylic acid sodium, specifically solid dispersion of N-(8-[2-Hydroxybenzoyl]-Amino) caprylic acid sodium with one or more active pharmaceutical ingredients, its process of preparation and pharmaceutical compositions comprising the same. The present invention further relates to the process of preparing pure N-(8-[2-Hydroxybenzoyl]-Amino) caprylic acid sodium (Salcaprozate sodium/SNAC).
The present invention relates to a process for the preparation of solid forms of Suvorexant (1) with at least one pharmaceutically acceptable excipient It further relates to a process for the preparation of amorphous form of Suvorexant (1). The present invention is further directed to a pharmaceutical composition comprising a solid dispersion of suvorexant with at least one pharmaceutically acceptable excipient and process for the preparation thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
The present invention relates to crystalline form of Mitapivat hemisulfate (1). The present invention further relates to a process for preparing crystalline form of Mitapivat hemisulfate (1) and pharmaceutical compositions thereof. The crystalline form of Mitapivat hemisulfate (1) has been characterized by X-Ray powder diffractogram, Differential scanning Calorimetry and Thermogravimetric analysis.
The present invention relates to an oral pharmaceutical composition of isavuconazonium or its pharmaceutically acceptable salts thereof. The present invention also relates to a process for preparing an oral pharmaceutical composition of isavuconazonium or its pharmaceutically acceptable salts thereof. It further relates to use of such compositions for the treatment of invasive aspergillosis or invasive Mucormycosis.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to solid forms of 8-quinolinesulfonamide, N- [4- [4(cyclopropyl methyl)-1-piperazinyl] carbonyl] phenyl]-sulfate of formula (1). Further, the present invention relates to solid dispersions of 8- quinolinesulfonamide, N- [4- [4(cyclopropyl methyl)-1-piperazinyl] carbonyl] phenyl]-sulfate of formula (1) with at least one pharmaceutically acceptable excipient and process for its preparation thereof. The present invention provides process for pure amorphous form of 8-quinolinesulfonamide, N- [4- [4(cyclopropyl methyl)-1-piperazinyl] carbonyl] phenyl]-sulfate of formula (1). Furthermore, solid forms of 8-quinolinesulfonamide, N- [4- [4(cyclopropyl methyl)-1-piperazinyl] carbonyl] phenyl]-sulfate of formula (1) prepared in the present invention is having purity at least 99% by HPLC.
An improved process for the preparation of N-ethyl-α-methyl-3-(trifluoromethyl) phenethylamine hydrochloride is provided, having purity greater than 99.5% by HPLC using highly pure 3-(trifluoromethyl) aniline hydrochloride as a key starting material. The disclosed provides process for the purification of N-ethyl-α-methyl-3-(trifluoromethyl) phenethylamine hydrochloride, which is substantially free of Impurity A and Impurity B.
C07C 211/29 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
The present invention relates to a process for the preparation of Suvorexant (1) having a purity greater than 99.5% by High-performance liquid chromatography (HPLC). The present invention also relates to novel process for the preparation of 5 (R)-1-benzyl-5-methyl-1,4-diazepane tartrate (7). The present invention further relates to a process for pure solid forms of Suvorexant (1).
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
10.
SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD
A pure amorphous form of 2-chloro-2′-deoxy-adenosine (Cladribrine (1)) complex with HPβCD is provided, wherein the percentage of crystallinity is less than 0.5% (w/w), or alternatively less than 0.2% (w/w). Also provided is a process for the preparation of amorphous form of Cladribine (1) complex with pharmaceutically suitable excipient having percentage of crystallinity less than 0.5%, or alternatively less than 0.2%. (w/w). Cladribine of formula (1)
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
11.
A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD)
The present invention relates to a novel process for the preparation of amorphous solid dispersion of 1-{3-[3-(4-chlorophenyl) propoxy] propyl} piperidine, hydrochloride with Hydroxypropyl beta-Cyclodextrin (HPβCD) (1) The present invention further relates to purification of Pitolisant (2). Formula (I)
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
12.
A PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM OF TAFAMIDIS
909090) less than 100 microns and specific surface area less than 30sq.m/g. The present invention relates to a stable oral dosage form comprising composition containing Tafamidis, particularly, a soft gel capsule comprising composition containing Tafamidis and to methods for their preparation. The present invention relates to a stable oral dosage form comprising composition containing Tafamidis which is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
13.
2,2'-BIINDOLINE]-5,5'-DISULFONATE AND PROCESS FOR ITS PREPARATION THEREOF
The present invention relates to solid forms of Disodium 3,3'-dioxo-[Δ2,2'-biindoline]- 5,5'-disulfonate and process for its preparation thereof. The present invention also relates to amorphous form and amorphous solid dispersion of Disodium 3,3'-dioxo- [Δ2,2'-biindoline]-5,5'-disulfonate is having purity greater than 99.0% (w/w) by HPLC. The present invention further relates to process for the preparation of crystalline form of 3,3'-dioxo-[2,2'-biindolinylidene]-5,5'-disulfonic acid is having purity greater than 99.0% (w/w) by HPLC.
The present invention relates to a pharmaceutical liquid dosage form of Trientine and/or its pharmaceutically acceptable salts thereof, which are suitable for oral administration. The present invention also relates to process of preparing the liquid dosage form and it's use for treatment of Wilson's disease and related diseases.
The present invention relates to a process for the purification of Manganese sulfate monohydrate (1). The present invention also specifically relates to a cost-effective process for the preparation of pharmaceutical grade Manganese sulfate monohydrate (1) having purity greater than 99.9998% (w/w).
The present invention relates to a process for the preparation of crystalline form A of N, N'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride (I).
A NOVEL PROCESS FOR THE PREPARATION OF 7 (4, 7- DIAZASPIRO [2.5] OCTAN-7-YL)-2-(2,8 DIMETHYLIMIDAZO[1,2-B] PYRID AZIN-6- YL) PYRIDO-4H-[1,2-A] PYRIMIDIN-4-ONE WITH NOVEL INTERMEDIATES
The present invention relates to a process for the preparation of 7-(4,7-diazaspiro [2.5] octan- 7-yl)-2-(2,8-dimethylimidazo[l,2-b] pyridazin-6-yl) pyrido-4H-[1,2-a] pyrimidin-4-one represented by the following structural formula (1) by employing novel intermediates of formulae (5), (6), (7), (9) and (13). (1) The present invention further relates to process for the purification of 7-(4,7-diazaspiro [2.5] octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b] pyridazin-6-yl) pyrido-4H-[1,2-a] pyrimidin-4-one (1), is with purity greater than 99.5% by High-performance liquid chromatography.
The present invention relates to solid forms of Pitolisant or its salt (1). It further discloses the solid dispersions of Pitolisant or salt (1) thereof in amorphous form and at least one suitable pharmaceutically acceptable excipient. The resent invention further relates the process for preparing solid dispersion of Pitolisant or salt (1) thereof.(I)
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
19.
PROCESS FOR THE PREPARATION OF SODIUM 4-(2-((1E,3E,5E,7Z)-7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO[e]INDOL-2(3H)-YLIDENE) HEPTA-1,3,5-TRIENYL)-1,1-DIMETHYL-1H-BENZO[e]INDOLIUM-3-YL) BUTANE-1-SULFONATE (INDOCYANINE GREEN)
A process for the preparation of substantially pure Indocyanine green of formula with purity greater than 99.0% is provided. More particularly, the embodiments relate to the process for the preparation of Indocyanine green of formula and its intermediates thereof. It further provides crystalline form I of Indocyanine green of formula and process thereof.
C09B 67/48 - Crystalline modifications of pigments or dyestuff
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
20.
AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- α -METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE HYDROCHLORIDE
The present invention relates to an improved process for the preparation of N-ethyl- α -methyl-3-(trifluoromethyl) phenethylamine hydrochloride (1), having purity greater than 99.5% by HPLC using highly pure 3-(trifluoromethyl) aniline hydrochloride (5) as a key starting material. The present invention provides process for the purification of N-ethyl-α -methyl-3-(trifluoromethyl) phenethylamine hydrochloride (1), which is substantially free of Impurity A and Impurity B.
The present invention relates to a novel process for the preparation of 2-[4-[2-[4-[1-(2-ethoxyethyl) benzimidazol-2-yl] piperidin-1-yl] ethyl] phenyl]-2-methyl propionic acid (I). It further relates to a process for the purification of Bilastine (I), is having purity greater than 99.0% by High performance liquid chromatography (HPLC).
C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
22.
SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPβCD
The present invention relates to a pure amorphous form of 2-chloro-2'-deoxy-adenosine (Cladribine (1)) complex with HPβCD, wherein the percentage of crystallinity is less than 0.5% (w/w), more preferably less than 0.2% (w/w). The present invention further relates to a process for the preparation of amorphous form of Cladribine (1) complex with pharmaceutically suitable excipient having percentage of crystallinity less than 0.5%, more preferably less than 0.2%. (w/w). Cladribine of formula (1)
The present invention relates to an improved process for the preparation of pharmaceutical grade of Sucroferric oxyhydroxide (1). More particularly, the present invention relates to a process for the preparation of Sucroferric oxyhydroxide (1) specific surface area of more than 16 m2/gm and having phosphate binding capacity by Ion Chromatography (IC) is at least 2.6 meq. of phosphate per 500 mg Iron and at least 0.2 mg P/mg of Iron.
The present invention relates to an improved process for the preparation of Sugammadex sodium (1). It further relates to a novel process for the purification of Sugammadex sodium (1) having impurity A less than 2% (w/w) and impurity E less than 0.1% (w/w)
The present invention relates to an improved process for the preparation of Sugammadex sodium (1). It further relates to a novel process for the purification of Sugammadex sodium (1) having impurity A less than 2% (w/w) and impurity E less than 0.1% (w/w)
NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND IT'S COMPLEXES WITH PARAMAGNETIC METAL IONS
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
26.
Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes
The present invention relates to an improved process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than 5 ppm and free gadolinium content less than 10 ppm, which is represented by the formula (1). The present invention further relates to an improved process for the preparation of calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclo decane-1,4,7-triacetic acid known as Calcobutrol (1a) and its sodium salt of formula (1b) with purity greater than 98.0%.
The present invention relates to an improved process for the preparation of pharmaceutical grade of Sucroferric oxyhydroxide (1). More particularly, the present invention relates to a process for the preparation of Sucroferric oxyhydroxide (1) specific surface area of more than 16 m2/gm and having phosphate binding capacity by Ion Chromatography (IC) is at least 2.6 meq. of phosphate per 500 mg Iron and at least 0.2 mg P/mg of Iron.
The present invention relates to an improved process for the preparation of Sugammadex sodium (1). It further relates to a novel process for the purification of Sugammadex sodium (1). More particularly, the present invention provides Sugammadex sodium (1) having purity more than 98% and impurity A less than 2 %( w/w) and impurity E less than 0.1% (w/w)
NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND IT'S COMPLEXES WITH PARAMAGNETIC METAL IONS
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).
Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium)
The present invention discloses a novel process for the preparation of gadolinium complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium of formula 1 and novel intermediates thereof.
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 227/02 - Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
C07C 269/04 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 271/02 - Carbamic acidsSalts of carbamic acids
C07C 303/04 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups
C07C 309/24 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
31.
Method for the preparation of sulfobutylether beta cyclodextrin sodium
The present invention relates to an improved method for the synthesis of sulfobutylether beta cyclodextrin sodium and to provide an amorphous form of sulfobutylether beta cyclodextrin sodium having a 1,4-butane sultone content less than 0.5 ppm. The present invention further provides sulfobutylether beta cyclodextrin sodium containing less than 35 IU/g of Bacterial endotoxins.
The invention relates to novel process for preparation of Tavaborole. The invention also relates to novel polymorphic forms of Tavaborole and process for preparation of those polymorphic forms. The invention also relates to process for purification of Tavaborole to obtain the Tavaborole in significantly high yield and substantially pure form.
PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES
The present invention relates to an improved process for the preparation of 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than 5 ppm and free gadolinium content less than 10 ppm, which is represented by the formula (1). The present invention further relates to an improved process for the preparation of calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclo decane-1,4,7-triacetic acid known as Calcobutrol (1a) and its sodium salt of formula (1b) with purity greater than 98.0 %.
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India)
Inventor
Pullagurla, Manik Reddy
Rangisetty, Jagadeesh Babu
Abstract
The present invention relates to an improved process for the preparation of Cetrorelix acetate (1). More particularly, the present invention relates to the purification of Cetrorelix acetate (1) by simple method.
C07K 1/16 - ExtractionSeparationPurification by chromatography
C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents
36.
PROCESS FOR THE PREPARATION OF SODIUM 4-(2-((1E,3E,5E,7Z)-7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO[e]INDOL-2(3H)-YLIDENE) HEPTA-1,3,5-TRIENYL)-1,1-DIMETHYL-1H-BENZO[e]INDOLIUM-3-YL) BUTANE-1-SULFONATE (INDOCYANINE GREEN)
A process for the preparation of substantially pure Indocyanine green of formula with purity greater than 99.0% is provided. More particularly, the embodiments relate to the process for the preparation of Indocyanine green of formula and its intermediates thereof. It further provides crystalline form I of Indocyanine green of formula and process thereof.
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
C09B 67/48 - Crystalline modifications of pigments or dyestuff
37.
SOLID FORMS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL] PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD] INDOL-6-ONE ((1S,4R)-7,7DIMETHYL-2-OXOBICYCLO [2.2.1] HEPT-1-YL) METHANESULFONIC ACID SALT (RUCAPARIB CAMSYLATE) AND THE PRERPARATION THEREOF
The present invention relates to solid forms of Rucaparib camsylate (1). More particularly the invention relates to solid forms comprising of crystalline form R1, R2, R3, R4, R5 and R6 of Rucaparib camsylate (1) and solid dispersions of Rucaparib camsylate (1) with suitable pharmaceutically acceptable excipients. It further discloses the process for preparing the crystalline forms and solid dispersions of Rucaparib camsylate (1).
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
38.
CRYSTALLINE FORMS OF (3Α, 5Β, 6Α, 7Α)-6-ETHYL-3, 7-DIHYDROXYCHOLAN-24-OIC ACID (OBETICHOLIC ACID) AND PROCESSES THEREOF
The present invention relates to the crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid, commonly known as Obeticholic acid (1). Further, the present invention also provides process for the preparation of Obeticholic acid crystalline forms thereof. More specifically, the present invention provides crystalline forms B1, B2, B3 and B4 of Obeticholic acid and the process for the preparation thereof.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
39.
IMPROVED PROCESS FOR THE PREPARATION OF 7-CYCLOPENTYL-N, N-DIMETHYL-2-(5-(PIPERAZIN-1-YL) PYRIDIN-2-YLAMINUTESO)-7H-PYRROLO[2,3-D] PYRIMIDINE-6-CARBOXAMIDE SUCCINATE (RIBOCICLIB SUCCINATE) AND ITS CRYSTALLINE FORMS THEREOF
The present invention relates to an improved process for the preparation of Ribociclib succinate (1) and the novel crystalline forms thereof. More particularly the invention relates to the process for the preparation of novel crystalline forms of Ribociclib succinate (1).
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
40.
Isosulfan blue, its crystalline form and process for preparation thereof
Provided is an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl](2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. It also relates to highly pure novel crystalline form of Isosulfan blue hydrate and its process for the preparation thereof. It also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.
C07C 303/04 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups
C07C 303/22 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids by reactions not involving the formation of sulfo or halosulfonyl groups
C07C 303/06 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups by reaction with sulfuric acid or sulfur trioxide
An improved method for the synthesis of substantially pure Permethrin having purity greater than 99.5% by Gas Chromatography provided. The embodiments also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.
The present invention relates to a novel process for the preparation of Docosanol (I). More particularly, the invention relates to a novel process for the preparation of Docosanol (I) in a substantially pure form with a purity level of greater than 99.5%. The invention also relates to novel crystalline forms of Docosanol (I) and process for preparation thereof.
C07C 31/125 - Monohydroxylic acyclic alcohols containing five to twenty-two carbon atoms
C07C 29/76 - SeparationPurificationStabilisationUse of additives by physical treatment
C07C 29/78 - SeparationPurificationStabilisationUse of additives by physical treatment by condensation or crystallisation
C07C 45/29 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of hydroxy groups
C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
C07C 29/147 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
C07C 45/38 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of C—O— functional groups to C=O groups being a primary hydroxy group
C07C 45/30 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
43.
Method for the synthesis of ferric oraganic compounds
The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.
The present invention relates to an improved method for the synthesis of substantially pure 1,2-ethanediamine, N, N'-bis(2-aminoethyl)-dihydrochloride (I). Formula (I). Ν,Ν'-bis (2-aminoethyl)-l,2-ethanediamine dihydrochloride (Trientine dihydrochloride)
The present invention relates to an improved method for the synthesis of sulfobutylether beta cyclodextrin sodium and to provide an amorphous form of sulfobutylether beta cyclodextrin sodium having a 1,4-butane sultone content less than 0.5 ppm. The present invention further provides sulfobutylether beta cyclodextrin sodium containing less than 35 IU/g of Bacterial endotoxins.
This invention relates to an improved method for the preparation of highly or substantially pure Indigotindisulfonate sodium (1). It further relates to the novel crystalline form I of Indigotindisulfonate sodium (1) and the process for its preparation.
The present invention describes an improved method for the synthesis of substantially pure Permethrin (1) having purity greater than 99.5% by Gas Chromatography (GC). The invention also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.
The invention relates to an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl] (2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N- ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. The invention also relates to highly pure novel crystalline form of Isosulfan blue (I) hydrate and its process for the preparation thereof. The invention also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.
C07C 303/00 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides
50.
NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM)
The present invention discloses a novel process for the preparation of gadolinium complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9- triazaundecanedioic acid disodium of formula 1 and novel intermediates thereof.
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
The present invention provides a novel and commercially viable process with high yield for the preparation of (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, also known as Belinostat (I). The invention also provides process for purification and novel crystalline form of Belinostat in substantially pure form. [Formula should be inserted here]
C07C 311/17 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
52.
NOVEL PROCESS FOR THE PREPARATION OF TAVABOROLE, ITS NOVEL POLYMORPHIC FORMS AND THE POLYMORPHS THEREOF
The invention relates to novel process for preparation of Tavaborole. The invention also relates to novel polymorphic forms of Tavaborole and process for preparation of those polymorphic forms. The invention also relates to process for purification of Tavaborole to obtain the Tavaborole in significantly high yield and substantially pure form.
Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
Novel methods for preparation of Carfilzomib and intermediates thereof with high stereo selection are reported. The synthetic procedures result in substantially pure Carfilzomib (I).
C07K 9/00 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequenceDerivatives thereof
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07D 303/36 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-VII) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. and intermediates involved in the synthesis.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-{4-(OCO-NH-CH2-CH2-NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.
The present invention describes a novel process for the preparation of Ethacrynate sodium. The process involves the treatment of Ethacrynic acid with equimolar amount of sodium salt of alkyl carboxylic acid in the presence of organic solvents. The product obtained by the process is substantially pure form (purity greater than 99%) and limits known impurities below 0.1% w/w. The process also relates to a crystalline form of Ethacrynate sodium and a process for its preparation. The process is efficient and cost effective method for the commercial scale production of substantially pure stable form of Ethacrynate sodium.
The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.
The invention provides a novel polymorph of Regadenoson. More particularly, the invention provides propylene glycol solvate of Regadenoson. The invention also provides a process for the preparation of propylene glycol solvate of Regadenoson.
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
59.
PROCESS FOR THE PREPARATION OF (S)-4-METHYL-N-((S)-1-(((S)-4-METHYL-1-((R)-2-METHYLOXIRAN-2-YL)-1-OXO PENTAN-2-YL) AMINO)-1-OXO-3-PHENYLPROPAN-2-YL)-2-((S)-2-(2-MORPHOLINOACETAMIDO)-4-PHENYLBUTANAMIDO) PENTANAMIDE
Novel methods for preparation of Carfilzomib and intermediates thereof with high stereo selection are reported. The synthetic procedures result in substantially pure Carfilzomib (I).
The present invention relates to an improved process for the preparation of Melphalan, more specifically the invention relates to an efficient process for the preparation of substantially pure Melphalan hydrochloride (I).
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 227/12 - Formation of amino and carboxyl groups
C07C 227/20 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino acids or derivatives thereof, e.g. hydrolysis of carbamates
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
61.
Process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide
The present invention relates to a novel process for the preparation of (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide.
The present invention describes an improved process for the industrial scale production of dimethyl fumarate. The process involves a one-pot ring opening reaction of maleic anhydride to monomethyl maleate and isomerization into the corresponding monomethyl fumarate in presence of a Lewis acid. Finally the mono methyl fumarate was converted into the dimethyl fumarate by an acid catalyzed esterification reaction.
C07C 67/333 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
63.
AN IMPROVED PROCESS FOR THE PREPARATION OF AGOMELATINE POLYMORPHIC FORM-1
The invention provides a process for preparation of polymorphic form I of Agomelatine comprising dissolving Agomelatine in a water miscible organic solvent to obtain Agomelatine solution (solution A), preparing a solution of water miscible organic solvent and water (solution B) and cooling to below 0 ºC, adding solution A to solution B at below 0 ºC and precipitating Agomelatine polymorphic Form 1.
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
64.
Process for the synthesis of dabigatran and its intermediates
The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-VII) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. and intermediates involved in the synthesis.
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention provides a novel polymorph of Regadenoson. More particularly, the invention provides propylene glycol solvate of Regadenoson. The invention also provides a process for the preparation of propylene glycol solvate of Regadenoson.
The present invention relates to an improved process for the preparation of Melphalan, more specifically the invention relates to an efficient process for the preparation of substantially pure Melphalan hydrochloride (I).
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
The invention discloses the synthesis of Etravirine via intermediate 4-((4-amino-5-bromo-6-chloropyrimidin-2-yl) amino)benzonitrile and process for the preparation of Etravirine of the formula-I.
NOVEL PROCESS FOR THE PREPARATION OF (1-{9-[(4S, 2R, 3R, 5R)-3, 4-DIHYDROXY-5-(HYDROXYMETHYL) OXOLAN-2-YL)-6-AMINOPURIN-2-YL} PYRAZOLE-4-YL)-N-METHYLCARBOXAMIDE
The present invention relates to a novel process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
69.
AN IMPROVED PROCESS FOR THE SYNTHESIS OF DABIGATRAN AND ITS INTERMEDIATES
The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-I), a pharmaceutically acceptable salt for the treatment of thromboses, cardiovascular diseases etc. and intermediates involved in the synthesis. [Formula should be inserted here]
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
70.
PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES
C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 229/76 - Metal complexes of amino carboxylic acids
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
72.
PROCESS FOR PREPARATION OF INTERMEDIATES OF BENDAMUSTINE
The present invention relates to a process for the preparation of 4-{5-{ Bis-(2-hydroxyl-ethyl)-amino}-1-methyl-1H-Benzoimidazol-2yl}-butyric acid alkyl ester of formula IV, a key intermediate in the process for the preparation of Bendamustine HCI (I)
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
73.
NOVEL POLYMORPH OF ELETRIPTAN HYDROBROMIDE AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to a novel crystalline polymorphic form D of Eletriptan Hydrobromide characterized by an XRD pattern with two theta values at 18.8., 20.5, 23.7, 24.2. The present invention also relates to a process for making Form D comprising treating Eletriptan in water or in a suitable organic solvent with hydrogen bromide and cooling to temperatures to the range of 10° C or sub-zero temperatures.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a novel process for the preparation of sodium 7-((3-Chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoate and intermediates. The invention also encompasses isolation of an essentially non-hygroscopic compound which is substantially pure.
The present invention relates to a novel process for the preparation of (R)-3-((1-methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole and its intermediates thereof.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
patents
